Solange Peters, MD, PhD, Discusses Key Abstracts Presented at the 2021 ESMO Congress

ESMO’s president, Solange Peters, MD, PhD, discussed a handful of key abstracts presented during the 3 Presidential Symposia sessions at the 2021 ESMO Congress.

CancerNetwork spoke with Solange Peters, MD, PhD, head of the medical oncology service and chair of thoracic oncology in the Oncology Department at the Centre Hospitalier Universitaire Vaudois and president of the European Society for Medical Oncology (ESMO), about key abstracts that read out at the 2021 ESMO Congress. Several of the trials, including the phase 3 DESTINY-Breast03 trial (NCT03529110), examining the use of fam-trastuzumab deruxtecan-nxki (Enhertu) vs trastuzumab emtansine (Kadcyla; T-DM1) in patients with HER2-positive metastatic breast cancer, as well as the phase 3 KEYNOTE-826 trial (NCT03635567), which assessed pembrolizumab (Keytruda) plus chemotherapy compared with chemotherapy alone in metastatic cervical cancer.


So, there are 3 Presidential [Symposia], which encompass the definition of practice changing abstracts… We have trastuzumab deruxtecan vs TDM-1 in HER2-positive metastatic breast cancer,1 [which is an] amazing trial. We have pembrolizumab plus chemotherapy vs chemotherapy for metastatic cervical cancer2, which is not-so-often observed in big sessions [and is] an amazing trial, too. Very important is the extension of the pembrolizumab indication in the [adjuvant] melanoma setting3, [which was] also presented today.

Tomorrow, we have also 2 breaking news [presentations] in castration-sensitive prostate cancer—one in early and 1 in late disease [with] these new combinations of drugs.4 We have the KRAS inhibitor adagrasib plus cetuximab (Erbitux), which also [has] amazing data in colorectal cancer.5 We [also] have [nivolumab]/chemotherapy in gastric cancer.6


  1. Cortés J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study. Presented at: European Society for Medical Oncology Annual Congress 2021; September 16-21, 2021; virtual. Abstract LBA1.
  2. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: randomized, double-blind, phase 3 KEYNOTE-826 study. Presented at: 2021 ESMO Congress; September 16-21, 2021; virtual. Abstract LBA2_PR.
  3. Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: efficacy and safety results from the KEYNOTE-716 double-blind phase 3 trial. Presented at: 2021 ESMO Congress; September 16-21, 2021; virtual. Abstract LBA3_PR.
  4. Attard G, Brown L, Clarke N, et al. Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021; virtual. Abstract LBA4.
  5. Mirati Therapeutics announces positive phase 2 topline results for investigational adagrasib in patients with KRAS G12C-mutated advanced non-small cell lung cancer. News release. Mirati Therapeutics, Inc. September 20, 2021. Accessed September 20, 2021.
  6. Janjigian YY, Ajani JA, Moehler M, et al. Nivolumab (nivo) plus chemotherapy (chemo) or ipilimumab (ipi) vs chemo as first-line (1L) Treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study. Presented at: 2021 ESMO Congress; September 16-21, 2021; virtual. LBA7.
Related Videos
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Related Content